IRIS
BANDINI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.344
NA - Nord America 2.057
AS - Asia 1.648
SA - Sud America 446
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 32
OC - Oceania 2
Totale 6.641
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.927
RU - Federazione Russa 1.177
SG - Singapore 494
CN - Cina 479
IT - Italia 437
BR - Brasile 370
HK - Hong Kong 286
SE - Svezia 246
VN - Vietnam 177
DE - Germania 170
FR - Francia 79
CA - Canada 63
GB - Regno Unito 59
FI - Finlandia 46
BD - Bangladesh 43
IN - India 37
AR - Argentina 34
TR - Turchia 30
MX - Messico 28
PL - Polonia 27
NL - Olanda 22
ID - Indonesia 18
JP - Giappone 18
ES - Italia 16
ZA - Sudafrica 15
AT - Austria 12
EC - Ecuador 12
IE - Irlanda 12
MY - Malesia 12
IQ - Iraq 10
GT - Guatemala 9
CO - Colombia 8
JM - Giamaica 8
LT - Lituania 8
AE - Emirati Arabi Uniti 6
MA - Marocco 6
NP - Nepal 6
PK - Pakistan 6
SA - Arabia Saudita 6
UA - Ucraina 6
VE - Venezuela 6
NI - Nicaragua 5
PY - Paraguay 5
BE - Belgio 4
CL - Cile 4
CW - ???statistics.table.value.countryCode.CW??? 4
GR - Grecia 4
HN - Honduras 4
CR - Costa Rica 3
IR - Iran 3
PH - Filippine 3
UZ - Uzbekistan 3
AL - Albania 2
AU - Australia 2
BB - Barbados 2
CZ - Repubblica Ceca 2
EG - Egitto 2
EU - Europa 2
JO - Giordania 2
KE - Kenya 2
KW - Kuwait 2
LV - Lettonia 2
MD - Moldavia 2
PR - Porto Rico 2
PT - Portogallo 2
SN - Senegal 2
SR - Suriname 2
SV - El Salvador 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GF - Guiana Francese 1
GH - Ghana 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MK - Macedonia 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
TT - Trinidad e Tobago 1
VC - Saint Vincent e Grenadine 1
Totale 6.537
Salva come PNG Salva come JPEG
Città #
Ashburn 280
Hong Kong 277
Singapore 254
Moscow 222
Dallas 202
San Jose 170
Milan 129
Council Bluffs 93
Shanghai 93
New York 87
Ho Chi Minh City 72
Beijing 69
Hefei 64
Princeton 56
Los Angeles 55
Lawrence 54
Lauterbourg 53
Santa Clara 46
São Paulo 35
Hanoi 34
Phoenix 33
Rome 29
Boardman 26
Munich 23
Brooklyn 22
Orem 22
Turin 22
Denver 21
Helsinki 19
Miano 19
Turku 19
North Bergen 18
Warsaw 18
Montreal 16
Tokyo 14
Tekirdağ 13
Atlanta 12
Boston 12
Dublin 12
Poplar 12
Rio de Janeiro 12
Seattle 12
Amsterdam 11
Chennai 11
Chicago 11
London 11
Da Nang 10
Florence 10
Frankfurt am Main 10
Johannesburg 10
Manchester 10
Mexico City 10
Nuremberg 10
Toronto 10
Guangzhou 9
Charlotte 8
Haiphong 8
Houston 8
Washington 8
Caxias do Sul 7
Kuala Lumpur 7
Pune 7
Stockholm 7
Vienna 7
Ankara 6
Can Tho 6
Catania 6
Fortaleza 6
Kingston 6
Querétaro 6
Salerno 6
Salvador 6
Bari 5
Brasília 5
Bắc Ninh 5
Central 5
Columbus 5
Guatemala City 5
Hanover 5
Lappeenranta 5
Livorno 5
Managua 5
Miami 5
Quito 5
Baltimore 4
Betim 4
Buffalo 4
Cabo Frio 4
Cesano Boscone 4
Detroit 4
Erbil 4
Genoa 4
Guayaquil 4
Lancaster 4
Las Vegas 4
New Delhi 4
San Francisco 4
Shenzhen 4
Silver Spring 4
São José 4
Totale 3.123
Salva come PNG Salva come JPEG
Nome #
Development of a novel signature integrating clinical, imaging and epigenetic information to tailor pelvic nodal treatment in prostate cancer 374
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 246
A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 188
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 178
Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting 151
A global approach to improving penile cancer care 150
Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma 148
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 140
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 136
A risk calculator predicting recurrence in lymph node metastatic penile cancer 129
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 127
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 127
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 122
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? 122
Causal contributors to tissue stiffness and clinical relevance in urology 122
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 121
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 115
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 114
DNA methylation alterations in prostate cancer: from diagnosis to treatment 113
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 113
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 113
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 112
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study 111
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer 107
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? 106
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups 102
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 102
Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy 101
Topographic modification of the extracellular matrix precedes the onset of bladder cancer 100
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 100
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 94
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma 90
The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis 85
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 79
Neoadjuvant chemotherapy for lymph node-positive penile cancer: Current evidence and knowledge 79
Revolutionizing care for rare genitourinary tumours 79
Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in children with proximal hypospadias 76
Targetable gene fusions and aberrations in genitourinary oncology 76
The effect of race on survival after local therapy in metastatic prostate cancer patients 72
Prevalence and surgical management of pubic hypertrophy in hypospadias patients: Results from a high-volume surgeon 71
Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition 71
Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma 70
Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis 70
Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations 70
The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC) 69
Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma 68
Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636–43 68
Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer 67
Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? 67
The new era of precision urobiome: RE: “Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study” by Chipollini et al 67
Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment 65
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab 64
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? 63
Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines 63
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration 63
Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies 63
The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer 62
Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55–65 62
Nomograms in urologic oncology, advantages and disadvantages 61
Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis 60
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study 59
Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer 58
Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited 56
Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233–9 55
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages 53
Data from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial 23
Diagnostic and treatment delays in penile cancer: a call to improve awareness and referral 22
Contemporary outcomes of salvage high-dose chemotherapy in advanced germ cell tumors: an analysis of the cellular therapy and immunobiology working party of the EBMT registry 13
Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma 10
Reply to Chao Quan, Jinbo Chen, and Jiao Hu's Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107–14 10
Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care? 10
Author Correction: A global approach to improving penile cancer care (Nature Reviews Urology, (2022), 19, 4, (231-239), 10.1038/s41585-021-00557-y) 8
Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference? 8
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer 8
Variations in Penile Cancer Management: Results From the Global Society of Rare Genitourinary Tumors Survey 7
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 7
HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage 6
Is chemoradiotherapy worth it in metastatic seminoma as first-line treatment? 6
How to get involved in clinical research: helpful tips 6
The Pros and Cons of 'Machination of Medicine' in Genitourinary Oncology Practice 5
Neoadjuvant and adjuvant multimodality treatments for patients with lymph node involvement 3
null 1
null 1
null 1
null 1
Totale 6.641
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202277 0 0 0 32 1 0 2 6 2 4 0 30
2022/2023407 129 98 31 10 3 41 11 45 8 3 13 15
2023/2024357 6 23 37 35 32 65 50 39 4 4 16 46
2024/20251.207 99 49 22 112 49 76 172 164 161 125 65 113
2025/20263.619 225 293 289 442 286 138 258 259 1.063 162 75 129
2026/2027914 138 187 178 411 0 0 0 0 0 0 0 0
Totale 6.641